At Privo Technologies, we are developing an entirely new class of targeted topical treatments intended for mucosal delivery.
We are developing our novel targeted treatments for worldwide markets at our facilities in the greater Boston area. Our proprietary nano-engineered platform is based on innovations in nanotechnology and material science with roots at MIT’s Koch Cancer Institute. Privo’s platform is designed to create robust treatments for a wide range of indications while reducing or limiting the treatment’s harmful side effects. We deliver drugs via the mucosa with the initial focus on oral cavity mucosa.
We are excited about building a pipeline of treatments with a range of product candidates in oncology, ophthalmology, hearing and gastrointestinal diseases. Our initial product candidate is a treatment for the critically under served worldwide market of oral cancer. Privo is currently conducting a human trial for its oral cancer treatment PRV111. See the Clinical Trial page.